Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Dengue dynamics and vaccine cost-effectiveness in Brazil.

Durham DP, Ndeffo Mbah ML, Medlock J, Luz PM, Meyers LA, Paltiel AD, Galvani AP.

Vaccine. 2013 Aug 20;31(37):3957-61. doi: 10.1016/j.vaccine.2013.06.036. Epub 2013 Jun 20.

2.

Economic impact of dengue illness and the cost-effectiveness of future vaccination programs in Singapore.

Carrasco LR, Lee LK, Lee VJ, Ooi EE, Shepard DS, Thein TL, Gan V, Cook AR, Lye D, Ng LC, Leo YS.

PLoS Negl Trop Dis. 2011 Dec;5(12):e1426. doi: 10.1371/journal.pntd.0001426. Epub 2011 Dec 20.

3.

Economic value of dengue vaccine in Thailand.

Lee BY, Connor DL, Kitchen SB, Bacon KM, Shah M, Brown ST, Bailey RR, Laosiritaworn Y, Burke DS, Cummings DA.

Am J Trop Med Hyg. 2011 May;84(5):764-72. doi: 10.4269/ajtmh.2011.10-0624.

4.

Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.

Wisløff T, Abrahamsen TG, Bergsaker MA, Løvoll Ø, Møller P, Pedersen MK, Kristiansen IS.

Vaccine. 2006 Jul 17;24(29-30):5690-9. Epub 2006 May 5.

PMID:
16735083
5.

Dengue vector control strategies in an urban setting: an economic modelling assessment.

Luz PM, Vanni T, Medlock J, Paltiel AD, Galvani AP.

Lancet. 2011 May 14;377(9778):1673-80. doi: 10.1016/S0140-6736(11)60246-8. Epub 2011 May 3.

6.

Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.

Tyo KR, Rosen MM, Zeng W, Yap M, Pwee KH, Ang LW, Shepard DS.

Vaccine. 2011 Sep 2;29(38):6686-94. doi: 10.1016/j.vaccine.2011.06.091. Epub 2011 Jul 13.

PMID:
21745516
7.

Estimating potential demand and supply of dengue vaccine in Brazil.

Amarasinghe A, Mahoney RT.

Hum Vaccin. 2011 Jul;7(7):776-80. doi: 10.4161/hv.7.7.16255. Epub 2011 Jul 1.

8.

[A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].

Vitale F, Barbieri M, Dirodi B, Vitali Rosati G, Franco E.

Ann Ig. 2013 Jan-Feb;25(1):43-56. doi: 10.7416/ai.2013.1905. Italian.

PMID:
23435779
9.

Meningococcal serogroup A, C, W₁₃₅ and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands.

Hepkema H, Pouwels KB, van der Ende A, Westra TA, Postma MJ.

PLoS One. 2013 May 31;8(5):e65036. doi: 10.1371/journal.pone.0065036. Print 2013.

10.

Cost of production of live attenuated dengue vaccines: a case study of the Instituto Butantan, Sao Paulo, Brazil.

Mahoney RT, Francis DP, Frazatti-Gallina NM, Precioso AR, Raw I, Watler P, Whitehead P, Whitehead SS.

Vaccine. 2012 Jul 6;30(32):4892-6. doi: 10.1016/j.vaccine.2012.02.064. Epub 2012 Mar 8.

PMID:
22406455
11.

Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.

Lloyd A, Patel N, Scott DA, Runge C, Claes C, Rose M.

Eur J Health Econ. 2008 Feb;9(1):7-15. Epub 2007 Mar 2.

PMID:
17333089
12.

Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children: a review.

Boonacker CW, Broos PH, Sanders EA, Schilder AG, Rovers MM.

Pharmacoeconomics. 2011 Mar;29(3):199-211. doi: 10.2165/11584930-000000000-00000. Review.

PMID:
21250759
13.

Cost-effectiveness of a pediatric dengue vaccine.

Shepard DS, Suaya JA, Halstead SB, Nathan MB, Gubler DJ, Mahoney RT, Wang DN, Meltzer MI.

Vaccine. 2004 Mar 12;22(9-10):1275-80.

PMID:
15003657
14.

The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.

Isaacman DJ, Strutton DR, Kalpas EA, Horowicz-Mehler N, Stern LS, Casciano R, Ciuryla V.

Clin Ther. 2008 Feb;30(2):341-57. doi: 10.1016/j.clinthera.2008.02.003. Review.

PMID:
18343273
15.

Valuing the broader benefits of dengue vaccination, with a preliminary application to Brazil.

Bärnighausen T, Bloom DE, Cafiero ET, O'Brien JC.

Semin Immunol. 2013 Apr;25(2):104-13. doi: 10.1016/j.smim.2013.04.010. Epub 2013 Jul 22. Review.

PMID:
23886895
16.

A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females.

Anonychuk AM, Bauch CT, Merid MF, Van Kriekinge G, Demarteau N.

BMC Public Health. 2009 Oct 31;9:401. doi: 10.1186/1471-2458-9-401.

17.
18.

Country- and age-specific optimal allocation of dengue vaccines.

Ndeffo Mbah ML, Durham DP, Medlock J, Galvani AP.

J Theor Biol. 2014 Feb 7;342:15-22. doi: 10.1016/j.jtbi.2013.10.006. Epub 2013 Oct 23.

19.

The economics of routine childhood hepatitis A immunization in the United States: the impact of herd immunity.

Armstrong GL, Billah K, Rein DB, Hicks KA, Wirth KE, Bell BP.

Pediatrics. 2007 Jan;119(1):e22-9.

PMID:
17200247
20.

TRIVAC decision-support model for evaluating the cost-effectiveness of Haemophilus influenzae type b, pneumococcal and rotavirus vaccination.

Clark A, Jauregui B, Griffiths U, Janusz CB, Bolaños-Sierra B, Hajjeh R, Andrus JK, Sanderson C.

Vaccine. 2013 Jul 2;31 Suppl 3:C19-29. doi: 10.1016/j.vaccine.2013.05.045.

PMID:
23777686
Items per page

Supplemental Content

Write to the Help Desk